| http://purl.uniprot.org/citations/8353278 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/8353278 | http://www.w3.org/2000/01/rdf-schema#comment | "The interleukin-6 (IL-6) signal is transduced through membrane-anchored gp130, which is associated with IL-6 receptor (IL-6R) in the presence of IL-6. Soluble forms of gp130 (sgp130) with molecular weights of 90 and 110 Kd were found in human serum. In the presence of recombinant IL-6 (rIL-6), serum sgp130 were capable of associating with serum sIL-6R. By the sandwich enzyme-linked immunosorbent assay, healthy human sera was shown to contain 390 +/-72 ng/mL of sgp130. A mouse pro-B-cell line-derived transfectant, BAF-130, expressing human gp130 was used to examine the function of serum sgp130. When supplemented with rIL-6, human serum induced DNA synthesis in BAF-130 cells, whereas the serum deprived of sIL-6R did not. In contrast, the DNA synthesis induced in BAF-130 cells by rIL-6-supplemented serum was increased when the serum was deprived of sgp130. These results indicated that serum sgp130 could negatively regulate the IL-6 signal. Recently, gp130 has been shown to be involved in the signaling processes of oncostatin M, leukemia inhibitory factor, and ciliary neurotropic factor, in addition to those of IL-6. Recombinant sgp130 showed inhibitory effect on the biologic function of such cytokines. This work implies physiologic roles of naturally produced serum sgp130 in modulating signals through gp130."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Kishimoto T."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Saito T."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Fukui H."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Yancopoulos G.D."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Yasukawa K."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Ohsugi Y."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Koishihara Y."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Taga T."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/author | "Narazaki M."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/date | "1993"xsd:gYear |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/name | "Blood"xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/pages | "1120-1126"xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/title | "Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130."xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://purl.uniprot.org/core/volume | "82"xsd:string |
| http://purl.uniprot.org/citations/8353278 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/8353278 |
| http://purl.uniprot.org/citations/8353278 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/8353278 |
| http://purl.uniprot.org/uniprot/P40189#attribution-88FB091E1DDF105BC8B678CA237CD291 | http://purl.uniprot.org/core/source | http://purl.uniprot.org/citations/8353278 |